SPOTLIGHT: Biolex touts hep C data

Biolex Therapeutics says that its Phase IIa trial of Locteron for chronic hepatitis C demonstrated positive results. A combination of the highest dose of Locteron evaluated and the antiviral drug ribavirin achieved an early virologic response in 100 percent of the hepatitis C patients treated. Release